Author of

• 20164

  +

  P1.15 - SCLC/Neuroendocrine Tumors (ID 701)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22795

    +

    P1.15-010 - Small Cell Lung Cancer: Experience of a Portuguese District Hospital (ID 9601)

    09:30 - 16:00  |  Presenting Author(s): Margarida Felizardo
    • Abstract

    Background:
    Small cell lung cancer (SCLC) originates from neuroendocrine-cell percursors and is characterized by rapid growth, high response rates and development of treatment resistance in patients with metastatic disease. In the past few years its heterogeneity in form of presentation, behaviour in response to therapy and time to progression has raised several questions.
    
    Method:
    Review of clinical files of patients with SCLC diagnosed between may 2012 and may 2017 in our hospital, according to demographic characteristics, risk factors, comorbidities, form of presentation and diagnostic approach, clinical stage, therapy performed and outcome.
    
    Result:
    In this period 46 patients were followed, of whom 80% were male, with an average age of 65.5 ± 9.2 years (min 45, max 88). About 96% had active or past smoking habits. Regarding to comorbidities, it was found that 61% had a history of chronic obstructive pulmonary disease, 57% of cardiovascular disease, 17% of type 2 diabetes mellitus and 9% had a history of a second tumor. One patient had a severe usual intersticial pneumonia. The most frequent forms of presentation were pneumonia (28%) followed by constitutional symptoms (15%). Histological diagnosis was achieved in most cases by bronchial biopsy (59%). At the time of diagnosis most of the patients had ECOG performance status 1 (67%) and presented stage IV disease (72%), followed by stage IIIB (13%). In 65% of patients therapy was conducted with palliative intent, 17% with curative intent and the remaining were eligible to Best Supportive Care. Only 1 patient performed surgery with curative intent. In the 30 patients submitted to first line palliative chemotherapy with platinum doublet and etoposide, 13 partial responses and 3 stable disease (according to RECIST 1.2 criteria) were observed. About outcome, there were 35 deaths (76%), 94% of whom were patients whose initial approach was palliative. Median survival was 246 days (CI 95%).
    
    Conclusion:
    SCLC comprehends a heterogeneous group of patients. In recent years diferent subtypes of SCLC have been identified and new therapeutic molecules have been tested in order to improve management of these tumors. More studies are necessary.